Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics 
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
VIP Receptors
More Information »Vasoactive intestinal peptide (VIP) receptors are a group of Gs -protein-coupled receptors that are currently divided into two subtypes; VPAC1 and VPAC2. They are widely distributed throughout the central nervous system.
VIP Receptor Products
Agonists |
|
Cat.No. |
Product Name / Activity |
| 2711 | Bay 55-9837 |
| Potent and selective VPAC2 agonist | |
| 2080 | PHM 27 (human) |
| Endogenous peptide product of human prepro-VIP | |
| 1182 | VIP (guinea pig) |
| Involved in neurotransmission, smooth muscle relaxation | |
| 1911 | VIP (human, rat, mouse, rabbit, canine, porcine) |
| Involved in neurotransmission, smooth muscle relaxation | |
| 3095 | [Ala2,8,9,11,19,22,24,25,27,28]-VIP |
| Highly selective VPAC1 agonist | |
| 1386 | [Ala11,22,28]VIP |
| Potent, highly selective VPAC1 agonist | |
Antagonists |
|
Cat.No. |
Product Name / Activity |
| 1172 | [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) |
| VIP antagonist | |
| 1905 | VIP (6-28) (human, rat, porcine, bovine) |
| VIP antagonist | |
| 3054 | [D-p-Cl-Phe6,Leu17]-VIP |
| Selective VIP receptor antagonist | |
Related Categories
Quick Order
Find multiple products by catalog number
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
New Therapies and Challenges in Asthma
Written by Peter J. Barnes
'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.
Tocris Events
Win a Kindle
11th Congress of the French Neuroscience Society
May 21 - 24, 2013
Lyon, France
Booth Number: 32